U.S. Livestock Vaccines Market Size, Share & Industry Analysis, By Type (Inactivated, Live Attenuated, Recombinant, and Others), By Animal Type (Bovine, Swine/ Porcine, Poultry, and Others), By Route of Administration (Oral, Parenteral, and Others), By Distributional Channel (Veterinary Hospitals, Veterinary Clinics, and Others), and Country Forecast, 2024-2032

The U.S. livestock vaccines market size was worth USD 2.48 billion in 2023 and is projected to grow at a CAGR of 6.5% during the forecast period.

The U.S. has seen a high prevalence of livestock and zoonotic diseases, which has increased the number of farm animals being vaccinated. This has led to the government's growing focus on preventing and controlling these diseases and the increase in the introduction of vaccines by the market players, which is expected to boost the demand for vaccines in the coming years.

For instance, according to the article published by National Foundation for Infectious Diseases in March 2023, in the U.S., approximately 5,000 animal rabies cases are reported each year.

The growing adoption of vaccines among farm animal owners and veterinarians driven, coupled with the awareness campaigns initiated to understand vaccination programmes for the treatment of livestock suffering from diseases, is expected to propel the market.

In 2020, during the COVID-19 pandemic, the market experienced slow growth in the U.S. The slow growth is attributed to fewer animal visits to hospitals and clinics for vaccination management compared to the pre-pandemic period.

LATEST TRENDS

Technological Upgradation Across Various Vaccines Types Identified as Key Market Trend

In recent years, the market players are continuously focusing on the technological advancement of various types of vaccines, such as live attenuated vaccine, recombinant vaccines, and vector vaccines to prevent the diseases spread among the farm animals effectively.

Furthermore, the advancements in live attenuation, i.e., modified live livestock vaccines, which offer advantages over other livestock vaccines, are anticipated to boost the adoption in the country.  For instance, In January 2021, Zoetis Services LLC launched Poulvac, Procerta HVT-IBD, a modified live vaccine for poultry to protect them from infectious bursal disease (IBD) viruses.

The advantages include the ability to provide rapid and long-lasting immunity and the potential for stronger and broader immune responses due to the presence of live, attenuated pathogens.

DRIVING FACTOR

Government Efforts to Promote Animal Health and Manage Livestock Related Diseases to Augment Growth Prospects

The government has increased its focus on implementing vaccination programs in the U.S. to protect the livestock population from contagious diseases. These vaccination programs are promoted by government as a preventive measure that is expected to encourage livestock owners and farmers to vaccinate their animals.

• In July 2020, the U.S. Department of Agriculture (USDA) invested USD 27.1 million to purchase Foot-And-Mouth Disease (FMD) vaccines for the National Animal Vaccine and Veterinary Countermeasures Bank. The purchase gave the government the means to respond to animal disease outbreaks.

The confluence of these factors is anticipated to boost the U.S. livestock vaccines market growth in the coming years.

In the U.S., 42 commercial flocks were impacted by the highly pathogenic avian influenza, and 220 equines were impacted by the West Nile virus in 2022.

RESTRAINING FACTORS

Growing Concerns Over Vaccine Failure Could Hinder the Market Growth 

Despite the increased adoption of vaccines for farm animals in the country, the risk associated with the adverse effects of these products is a point of concern. These livestock vaccines may occasionally lead to allergic reactions, injection site reactions, or other animal side effects. These adverse effects are anticipated to create hesitancy among livestock animal owners to continue vaccinating their livestock, significantly impacting vaccine adoption rates in the country.

SEGMENTATION

By Type Analysis

Based on type, this market is segmented into inactivated, live attenuated, recombinant, and others.

The live attenuated segment held a larger U.S. livestock vaccines market share in 2022 due to the increasing number of launches of advanced live attenuated vaccines for farm animals coupled with the growing outbreaks of diseases in the country.

• For instance, in February 2020, Merck Animal Health (Merck & Co., Inc.) launched Nasalgen 3, a modified live virus for cattle, to prevent them from pneumonia-causing viral pathogens.

Furthermore, the development of live attenuated vaccines for swine which are given intramuscularly is expected to boost the segmental growth.

By Animal Type Analysis

Based on the animal type, the market is segmented into bovine, swine/ porcine, poultry, and others.

The poultry segment is projected to grow at the highest CAGR during the forecast period, 2023-2030. The highest CAGR is due to the increasing initiatives by companies to expand their poultry vaccine portfolio through product launches in the market.

• For instance, in October 2020, Boehringer Ingelheim International GmbH’s U.S. Animal Health Business launched VAXXITEK HVT+IBD+ILT, a recombinant vaccine to protect poultry from three diseases.

Furthermore, the presence of livestock and zoonotic diseases in poultry is expected to boost the adoption of vaccines, thereby propelling segmental growth.

By Route of Administration Analysis

Based on route of administration, the U.S. livestock vaccines market is segmented into oral, parenteral, and others.

In 2022, the parenteral segment held a larger share of the market. The segmental growth is attributed to the continuous research and development in the parenteral vaccines by leading players is further anticipated to lead to a significant growth of this segment during the forecast period.

• For instance, in January 2021, Zoetis Services LLC launched Poulvac Procerta HVT-IBD, a subcutaneous injection, which provides early protection against the contemporary infectious bursal disease (IBD) viruses confronting U.S. broilers.

By Distribution Channel Analysis

Based on distribution channel, the U.S. livestock vaccines market is segmented into veterinary hospitals, veterinary clinics, and others.

The veterinary clinics held a larger share in 2022 and is expected to grow at the highest CAGR during the forecast period. The growth is due to increasing demand for vaccines for farm animals, increased animal disease prevalence, and increased investment by governments and other organizations to improve veterinary clinics.

KEY INDUSTRY PLAYERS

In terms of the competitive landscape, the market depicts the presence of prominent and emerging companies operating in the market. Leading market players, such as Boehringer Ingelheim International GmbH, Merck Animal Health (Merck & Co., Inc.), and Zoetis Services LLC, have a significant market share. Boehringer Ingelheim International GmbH is a prominent company due to its strong direct presence and broad vaccine portfolio for farm animals.

Some other companies with a considerable presence in the U.S. market include Virbac, Phibro Animal Health Corporation, Vaxxinova International BV and Others, and other small & medium-sized players. These companies are focusing on strategic moves, such as launching livestock vaccines to strengthen their portfolio is expected to propel their share in the market.

LIST OF KEY COMPANIES PROFILED:

• Boehringer Ingelheim International GmbH (Germany)


• Virbac (France)


• Merck Animal Health (Merck & Co., Inc.) (U.S.)


• Zoetis Services LLC (U.S.)


• Ceva (France)


• Elanco (U.S.)


• Neogen Corporation (U.S.)

KEY INDUSTRY DEVELOPMENTS: 

• July 2023- The College of Veterinary Medicine of the Kansas State University announced the inauguration of a Center on Vaccine Evaluation and Alternatives for Antimicrobials (CVEAA). The center will support research and development of new and innovative livestock and animal vaccines.


• January 2021- Zoetis Services LLC launched Poulvac, Procerta HVT-IBD vaccine, to protect poultry from infectious bursal disease (IBD) viruses and broadened its product portfolio.


• August 2020 - Merck Animal Health (Merck & Co., Inc.) gained rights to VECOXAN, including in the U.S., for calves and lambs to prevent them from coccidiosis.

REPORT COVERAGE

The market report provides a detailed analysis of the market. It focuses on key aspects, such as vaccination programs, veterinary vaccination rates, and market dynamics. Additionally, it includes an overview of market segments, key industry developments such as mergers and acquisitions, and technological advancements in the market. Besides this, the report also offers insights into the epidemiology of key animal diseases in the country. Additionally, it encompasses the impact of COVID-19, and the industry overview during the pandemic is covered in the report.

Report Scope & Segmentation